Visual acuity evaluation of patients of Behcet disease on adalimumab

Abstract

Intruduction Behcet uveitis (BU) is one of major criteria of Behcet disease (BD) that end in macular structural damage.(Yalçındağ, Temel, Şekkeli, & Kar, 2021) Adalimumab (ADA) , which is an anti-TNF alpha biological drug, has proven higher safety in controlling Behcet uveitis over traditional treatment.(van der Houwen et al., 2023) Aim of study Evaluation of visual acuity (VA) in patients of BD on adalimumab. Patients and methods The study was a case control study. The study included 60 eyes from 60 BU patients that divided into 2 groups. The study was conducted at Ophthalmology department, Minia University Hospital in Egypt between february 2023 and August 2023. Results Patient on ADA therapy is very effective in recovery of Visual acuity in BU. This makes ADA has higher preference for achieving better visual prognosis in patients of BU rather than traditional therapy. Conclusion ADA is better as a first line of therapy in patients of BD associated with uveitis.